# Effect of the Zurich resource model teaching module on adherence to self-monitoring and to the written action plan in patients with asthma: a randomised controlled trial

Submission date	Recruitment status No longer recruiting	<ul><li>Prospectively registered</li></ul>		
19/10/2006		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
20/11/2006	Completed	[X] Results		
<b>Last Edited</b> 06/01/2021	Condition category Respiratory	[] Individual participant data		

#### Plain English summary of protocol

Not provided at time of registration

## Contact information

## Type(s)

Scientific

#### Contact name

Dr Claudia Steurer-Stey

#### Contact details

University Hospital Zurich Centre for Interdisciplinary Patient Education Zurich Switzerland 8091

claudia.stey@usz.ch

# Additional identifiers

**EudraCT/CTIS** number

**IRAS** number

ClinicalTrials.gov number

## Secondary identifying numbers

N/A

# Study information

#### Scientific Title

Effect of the Zurich resource model teaching module on adherence to self-monitoring and to the written action plan in patients with asthma: a randomised controlled trial

#### **Study objectives**

New methods are needed to improve adherence of asthma patients to a written personal action plan. With this trial we aim to provide evidence about the usefulness of an asthma unspecific educational course to achieve the goal of better adherence.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Cantonal Ethics Committee of the Canton Zurich, approved on the 18th October 2005 (ref: KEK-StV-Nr:29/05).

#### Study design

Randomised controlled trial

#### Primary study design

Interventional

#### Secondary study design

Randomised controlled trial

## Study setting(s)

Not specified

#### Study type(s)

Treatment

#### Participant information sheet

#### Health condition(s) or problem(s) studied

Asthma

#### Interventions

Zurich Resource Model (ZRM) training:

ZRM is thought to motivate the patient and to enable the patient to sense and interpret signs of deterioration more adequately and thereby improves the adherence in following the action plan. The ZRM model is based on findings in neurosciences and psychological theory. The ZRM model integrates treatment strategies from psychological as well as behavioral, body-oriented, and supportive-humanistic methods. ZRM training follows a specific manual and is suitable equally

for work with individuals and with groups, with adolescents and adults. Patients randomised to the ZRM group have a two day ZRM training in an outpatient setting followed by three ZRM refreshers of two hours for a repetition of important concepts after four, ten and 14 weeks.

#### Control group with usual care:

Usual care means treatment according to asthma guidelines which consists of clinical visits, adequate treatment and education in self-management with instruction in a personal Peak Expiratory Flow (PEF) and symptom based action plan. Patient education will include three main dimensions, knowledge (pathophysiology of the disease, effects and side effects of drugs) skills (inhalation technique and peak flow/symptom monitoring) and behaviour (instruction in the use of a written action plan, self-management). All patients included in the study will get that kind of patient education in a uniform defined way at the Medical Policlinic and Centre for interdisciplinary patient education. Part of the education (knowledge, inhalation technique, use of a peak-flow meter and monitoring) will be delivered in group trainings, while self-management with a personal action plan will be instructed individually.

Assessments will be made after one, three, six and 12 months.

#### Intervention Type

Behavioural

#### Primary outcome measure

To assess if patients with not optimally controlled asthma, who are treated according to GINA Guidelines and who participate in a ZRM course better adhere to:

- 1. Self-monitoring (PEF and symptoms);
- 2. Self-management according to the written personal action plan; and
- 3. Preventive strategies for known personal triggers, compared with patients treated according to GINA Guidelines alone.

#### Secondary outcome measures

To assess whether asthma patients participating in the ZRM training achieve better patient-assessed asthma control (asthma control questionnaire) and motivation and self-efficacy for self-management.

#### Overall study start date

04/10/2005

#### Completion date

04/02/2007

# **Eligibility**

#### Key inclusion criteria

- 1. Males and females of full legal age (18 years old and elder)
- 2. Persistent not optimally controlled asthma according to the Global Initiative on Asthma (GINA) guidelines (symptoms during day, or night time symptoms, or limitation in daily activities or sports because of asthma, or need for rescue medication or unscheduled visits due to exacerbations in the last six months)
- 3. Asthma is defined by history, symptoms and more than 12% reversibility of airflow obstruction after beta2-mimetika inhalation

#### Participant type(s)

**Patient** 

#### Age group

Adult

#### Lower age limit

18 Years

#### Sex

Both

#### Target number of participants

60

#### Total final enrolment

60

#### Key exclusion criteria

- 1. Psychiatric diagnosis such as major depression, schizophrenia, substance abuse or personality disorders
- 2. Other lung diseases: Chronic Obstructive Pulmonary Disease (COPD), lung cancer, fibrosis, sarcoidosis
- 3. Insufficient knowledge of German language to follow Zurich Resource Model (ZRM) course and /or to complete questionnaires

#### Date of first enrolment

04/10/2005

#### Date of final enrolment

04/02/2007

## Locations

#### Countries of recruitment

Switzerland

# Study participating centre University Hospital Zurich

Zurich Switzerland 8091

# Sponsor information

#### Organisation

AstraZeneca (Switzerland)

#### Sponsor details

Grafenau 10 Zug Switzerland 6301 +41 41 7257575 info@astrazeneca.ch

#### Sponsor type

Industry

#### Website

http://www.astrazeneca.ch

#### **ROR**

https://ror.org/034rhks82

# Funder(s)

### Funder type

Industry

#### **Funder Name**

AstraZeneca (Switzerland)

#### Alternative Name(s)

AstraZeneca PLC, Pearl Therapeutics

#### **Funding Body Type**

Government organisation

#### **Funding Body Subtype**

For-profit companies (industry)

#### Location

**United Kingdom** 

# **Results and Publications**

# Publication and dissemination plan

Not provided at time of registration

# Intention to publish date

# Individual participant data (IPD) sharing plan

# IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results		06/01/2021	Yes	No